• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by T2 Biosystems Inc.

    11/6/24 9:01:48 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care
    Get the next $TTOO alert in real time by email
    SC 13G 1 sc13g10871ttoo_11062024.htm

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. )1

     

    T2 Biosystems, Inc.

     (Name of Issuer)

    Common Stock, par value $0.001 per share

     (Title of Class of Securities)

    89853L302

     (CUSIP Number)

    October 30, 2024

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 89853L302

     

      1   NAME OF REPORTING PERSON  
             
            JACOB SAFIER  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         1,000,000  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         -0-  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              1,000,000  
        8   SHARED DISPOSITIVE POWER  
               
              -0-  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,000,000  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.7%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    2

    CUSIP No. 89853L302

      1   NAME OF REPORTING PERSON  
             
            JSAF HOLDINGS, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         1,000,000  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         -0-  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              1,000,000  
        8   SHARED DISPOSITIVE POWER  
               
              -0-  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,000,000  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.7%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 89853L302

    Item 1(a).Name of Issuer:

     

    T2 Biosystems, Inc. (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    101 Hartwell Ave.

    Lexington, MA 02421

     

    Item 2(a).Name of Person Filing:
    Item 2(b).Address of Principal Business Office or, if None, Residence:
    Item 2(c).Citizenship:

    JSAF Holdings, LLC (“JSAF”)
    c/o The Wolfson Group
    One State Street Plaza, 29th Floor
    New York, NY 10004
    Citizenship: United States

    Jacob Safier
    c/o The Wolfson Group
    One State Street Plaza, 29th Floor
    New York, NY 10004
    Citizenship: United States

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    89853L302

     

    4

    CUSIP No. 89853L302

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    As of the date hereof:

    JSAF beneficially owns 1,000,000 Shares.

    Jacob Safier, as the portfolio manager of the T2 Biosystems, Inc. investment by JSAF, may be deemed to beneficially own the Shares owned by JSAF and, therefore, may be deemed to beneficially own 1,000,000 Shares.

    (b)Percent of class:

     

    As of the date hereof, JSAF beneficially owned and Jacob Safier may be deemed to beneficially own 5.7% (based upon 17,479,954 Shares outstanding, which is the number of Shares reported as outstanding in the Issuer’s Quarterly Statement on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024).

     

    5

    CUSIP No. 89853L302

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    1,000,000 Shares.

    (ii)Shared power to vote or to direct the vote:

     

    0 Shares.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    1,000,000 Shares

    (iv)Shared power to dispose or to direct the disposition of:

     

    0 Shares.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    6

    CUSIP No. 89853L302

    SIGNATURE

     

    After reasonable inquiry and to the best of his or her knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 6, 2024

     

      JSAF Holdings, LLC
       
      By:

    /s/ Jacob Safier

        Name: Jacob Safier
        Title: Manager

     

     

     

    /s/ Jacob Safier

      Jacob Safier

    7

    Get the next $TTOO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TTOO

    DatePrice TargetRatingAnalyst
    2/18/2022$0.70Neutral → Buy
    Alliance Global Partners
    More analyst ratings

    $TTOO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Liebman Seymour

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:58:44 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Giffin Brett A.

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:55:13 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Adams Laura Lee

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:46:12 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • T2 Biosystems upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded T2 Biosystems from Neutral to Buy and set a new price target of $0.70

      2/18/22 10:16:52 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners resumed coverage on T2 Biosystems with a new price target

      Alliance Global Partners resumed coverage of T2 Biosystems with a rating of Neutral and set a new price target of $1.65 from $2.40 previously

      3/5/21 7:31:44 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems downgraded by Alliance Global Partners with a new price target

      Alliance Global Partners downgraded T2 Biosystems from Buy to Neutral and set a new price target of $2.40 from $2.60 previously

      1/27/21 8:12:03 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care